Corbus Pharmaceuticals Holdings Inc (CRBP)
6.93
+0.54
(+8.45%)
USD |
NASDAQ |
Mar 22, 16:00
6.93
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 28.91M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -53.25% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 18.77 |
| Price to Book Value | 0.8763 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.02% |
News
Headline
Wire
Time (ET)
SA Breaking News
03/21 10:03
PR Newswire
03/17 08:34
PR Newswire
03/14 16:35
PR Newswire
03/07 08:00
PR Newswire
03/06 08:00
Yahoo
03/02 08:00
Yahoo
02/13 11:27
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | -4.09 | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | -3.30 | -1.80 | -83.33% | |
| 05/10/2022 | -- | Results | Q1 2022 | -2.40 | -2.55 | 5.88% | |
| 03/08/2022 | -- | Results | Q4 2021 | -2.40 | -3.23 | 25.58% | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.60 | -3.30 | 81.82% | |
| 08/12/2021 | -- | Results | Q2 2021 | -4.50 | -3.75 | -20.00% | |
| 05/13/2021 | -- | Results | Q1 2021 | -4.20 | -4.80 | 12.50% | |
| 03/15/2021 | 08:30 EST | Earnings Call | Q4 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus’ internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells. |
| URL | https://www.corbuspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 21, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 34.84M |
| Net Income (TTM) | -42.35M |
| Total Assets (Quarterly) | 66.31M |
| Total Liabilities (Quarterly) | 33.32M |
| Shareholders Equity (Quarterly) | 32.99M |
| Cash from Operations (TTM) | -37.54M |
| Cash from Investing (TTM) | 30.07M |
| Cash from Financing (TTM) | -0.5336M |
Ratings
Profile
Edit
| Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus’ internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells. |
| URL | https://www.corbuspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CRBP Tweets |